Jennifer Dunlap

19PUBLICATIONS

126CO-AUTHORS

Gene and molecular therapyMolecular targetsHaematological tumoursMedical molecular engineering of nucleic acids and proteinsRegenerative medicine (incl. stem cells)

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (19)

Sort by Publication Date:

|Jul 02, 2026

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

|Jun 02, 2026

Sphingosine-1-phosphate receptor modulators resensitize FLT3-ITD acute myeloid leukemia cells with NRAS mutations to FLT3 inhibitors.

|Jun 01, 2026

Dynamic genetic and nongenetic RAS pathway activation drives resistance to FLT3 and BCL2 inhibitor therapy.

|Mar 17, 2026

Phase 1b study of ABBV-744, a novel, selective BET inhibitor, as monotherapy for patients with myelofibrosis.

John O Mascarenhas, Laura Maria Fogliatto, Steven D Green

|Feb 03, 2026

Clinical outcomes of older patients with NPM1-mutated or KMT2A-rearranged AML before menin inhibitors: a Beat AML report.

Joshua F Zeidner, Jayanshu Jain, Rina Li Welkie

|Dec 04, 2025

Sphingosine-1-phosphate receptor modulators resensitize FLT3-ITD acute myeloid leukemia cells with <i>NRAS</i> mutations to FLT3 inhibitors.

Aditi Chatterjee, Moaath K Mustafa Ali, Christopher M Bailey

Pageof 4

Frequent Collaborators

Joshua F Zeidner

Brian J Druker

Curtis Lachowiez

Alice S Mims

Rina Li Welkie

Catherine Smith

Yazan Madanat

Alexander Perl

Eytan M Stein

Vu H Duong

Frequent Collaborators

Joshua F Zeidner

Brian J Druker

Curtis Lachowiez

Alice S Mims